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Background: Infective endocarditis (IE) in dogs is associated with severe disease and
a high case fatality rate but often presents with nonspecific clinical signs.
Hypothesis/Objectives: Serum concentration of cardiac troponin-I (cTnI) is elevated
in dogs with IE and can differentiate dogs with IE from dogs with other diseases with
similar clinical features. Concentration of serum cTnI is negatively correlated with
survival time in dogs with IE.
Animals: Seventy-two client-owned dogs; 29 with IE, 27 with stage-B myxomatous
mitral valve disease (MMVD), and 16 with immune-mediated disease (IMD).
Methods: Retrospective clinical cohort study. Concentration of serum cTnI was
measured in all dogs at time of diagnosis. Clinical findings and echocardiographic
interpretation were also recorded. Statistical analyses included Kruskal-Wallis test,
pairwise Mann-Whitney U tests, receiver operator characteristic, and Cox propor-
tional hazards.
Results: Serum concentration of cTnI was significantly higher in the IE group
(0.69 ng/mL [0.03-80.8]) than in the MMVD (0.05 ng/mL [0.02-0.11], P < .001) and
IMD groups (0.05 ng/mL [0.03-0.57], P < .001). Increased cTnI was a moderately
accurate predictor of IE (area under the curve 0.857 (95% confidence interval
[CI] 0.745-0.968, P < .001). A cTnI cutoff of 0.625 ng/mL had 100% specificity (95%
CI 90%-100%) and 52% sensitivity (95% CI 33%-70%) in this study sample. There
was no association between cTnI concentration and survival time in dogs with IE
(hazard ratio 1.013, 95% CI 0.993-1.034, P = .2).
Conclusions and Clinical Importance: Cardiac troponin-I concentrations are higher in
dogs with IE compared to dogs with preclinical MMVD or IMD. In dogs with a compati-
ble clinical presentation, serum cTnI concentrations >0.625 ng/mL are supportive of IE.
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1 | INTRODUCTION
Infective endocarditis (IE) is a microbial infection causing inflammation
of the endothelial surface of at least 1 of the heart valves or the endo-
cardial layer of the heart chambers1,2 (Figure 1). Despite the severe dis-
ease and high case fatality rate associated with IE in dogs, a definitive
diagnosis can often be challenging antemortem because of nonspecific
clinical signs,1-3 although gross and histopathologic examination of the
affected tissue can prove conclusive. Antemortem diagnosis commonly
relies upon satisfaction of the modified Duke criteria,4 a scoring system
that has been adapted from human medicine5,6 and consists of major
and minor criteria. Depending on which criteria are met, the diagnosis of
IE is classified as definitive, possible, or rejected.
Although the modified Duke criteria represent a practical and rea-
sonable approach to the diagnosis of IE in dogs, there are inevitable
limitations. For instance, 1 of the major criteria, novel valve insuffi-
ciency, has poor specificity, in part because of the high prevalence of
myxomatous mitral valve disease (MMVD) in dogs.7 The presence of
MMVD can also make an echocardiographic diagnosis more challeng-
ing, as subtle IE lesions can be confused with or obscured by myxoma-
tous changes. Additionally, the minor criteria mostly consist of
systemic clinical signs, including pyrexia, and evidence of thromboem-
bolic disease. These signs are nonspecific and can be present in many
noncardiac diseases, most notably immune-mediated disease (IMD),
which is itself a minor criterion. Thus, making an antemortem diagno-
sis of IE is challenging, particularly as the clinical findings overlap con-
siderably with those of MMVD and IMD.
The circulating serum concentration of cardiac troponin-I (cTnI)
often increases with myocardial inflammation and necrosis8,9 and to a
lesser extent with acquired heart diseases such as MMVD10 and
dilated cardiomyopathy.11 Other possible causes of abnormally high
serum cTnI concentration in dogs include azotemia12 and systemic
diseases that might result in secondary myocardial injury, such as gas-
tric dilatation volvulus,13 pyometra,14 and adder envenomation.15
Increases in circulating cTnI concentrations are common in humans
with IE, in whom abnormal cTnI concentrations are also associated with
poor outcomes.16-19 However, the potential utility of cTnI as a diagnostic
or prognostic marker in dogs with IE has not been reported.
The primary aim of this retrospective study was to determine
whether the serum concentration of cTnI could differentiate dogs
with IE from 2 control groups, 1 with MMVD and another with IMD.
A secondary objective was to determine whether serum concentra-
tion of cTnI in dogs with IE was associated with survival time. We
hypothesized that serum cTnI concentration would be significantly
higher in dogs with IE than those in either control group, and that
increased cTnI concentration would be associated with a shorter
survival time in dogs with IE.
2 | METHODS
Computerized records from 2 veterinary teaching hospitals (Langford
Vets, University of Bristol, UK; Department of Small Animal Clinical
Science, School of Veterinary Science, University of Liverpool, UK) were
retrospectively searched to identify dogs diagnosed with IE, on the basis
of either the modified Duke criteria (Table 1) or the opinion and experi-
ence of the attending cardiology diplomate. Dogs with MMVD or IMD
were all recruited from a single center. Dogs from all groups were
F IGURE 1 Endocarditis lesions in 3 dogs showing: A, a typical
lesion of the aortic valve (arrowhead); B, a lesion of the cranial mitral
valve leaflet (arrowhead); and C, two mural lesions of the endocardial
surface of the left ventricular apex (arrowheads)
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eligible for inclusion if they had either serum cTnI measured at the time
of diagnosis, or if they had a blood sample taken at diagnosis which was
stored and available for subsequent analysis. Dogs were excluded if the
blood sample was taken more than 7 days before or after diagnosis.
Stored serum samples were kept at 80C. In the MMVD group, dogs
with current or previous signs of congestive heart failure7 were
excluded. Other exclusion criteria across all groups were a concurrent
diagnosis of neoplasia, azotemia (creatinine >1.40 mg/dL), or any other
known disease which could affect cTnI concentration.
Diagnoses of IE or MMVD were made by a cardiology diplomate,
or resident under supervision, and echocardiography was performed
in all patients. Dogs in the IMD group were only included if their clini-
cal signs subsequently responded to steroid treatment. They did not
need to have undergone an echocardiogram in order to be included.
However, IMD patients were excluded if they had clinical signs that
were subsequently found to be caused by cardiac disease. Each diag-
nosis of IMD was made by an internal medicine diplomate or resident
under supervision.
The serum concentration of cTnI was measured using 1 of 2 assays
(IMMULITE 2000 Troponin I, a two-site chemiluminescent immunoas-
say developed for cTnI measurement from Siemens Healthcare Diag-
nostics Inc, Tarrytown, NY, USA; AIA-900 troponin-I, a second-
generation immunoassay from Tosoh Bioscience, Tessenderlo, Belgium),
depending on which center the patient was recruited from. Both assays
used chemiluminescent immune-assay technology, and the reference
interval for each center was considered <0.1 ng/mL.20,21
Data recorded included patient body weight (classified as >15 kg
yes/no), age, breed, sex, concurrent disease, the presence of pyrexia
(rectal temperature >39.4C) and echocardiographic interpretation
(MMVD, IE, or normal). For the IE group, endocarditis lesion location,
predisposing factors identified (immunosuppressive treatment, con-
genital disease of the aortic valve, or left ventricular outflow tract),
the presence of a novel heart murmur, results of blood culture and
Bartonella henselae antibody titers (normal <1:120), and the presence
of immunologic phenomena or thromboembolic disease were also
recorded where available, as were date of last contact and status
(alive or dead) in order to calculate survival time after diagnosis.
2.1 | Statistical analysis
For continuous data, normality was assessed graphically and using a
Shapiro-Wilk test. Categorical data were compared using a Chi-square
or Fisher's exact test. Serum concentration of cTnI, body weight, sex,
age, and rectal temperature were compared across the 3 groups using
Kruskal-Wallis tests, with post hoc pairwise Mann-Whitney U tests
for between-group comparisons with Bonferroni corrections. Receiver
operator characteristic (ROC) curve analysis was performed to pro-
duce a range of cutoff values for serum cTnI concentration to discrim-
inate dogs with IE from those with MMVD and IMD. Finally, Cox
proportional hazards analysis was performed to explore associations
between serum cTnI concentration and survival time in patients with
IE. All statistical analyses were performed using commercially available
software (IBM SPSS 26 for Mac 10, IBM (UK) Ltd, Portsmouth;
TABLE 1 Suggested modified Duke criteria for diagnosis of
infective endocarditis in dogs (adapted from MacDonald et al).1 A
definitive diagnosis can be made if 2 major or 1 major and 2 minor
criteria are fulfilled. Diagnosis is classified as possible if 1 major and 1
minor criteria are met, or if 3 minor criteria are met, or rejected if a
firm alternative explanation of clinical signs are made or clinical signs
resolve with fewer than 4 days of treatment
Criteria Specific findings
Major 1. Echocardiographic valve lesion with typical
characteristics of endocarditis:
• Oscillates independently of valve motion
• Associated with atrial aspect of mitral valve or
ventricular aspect of aortic valve
2. Positive blood cultures:
• ≥2 positive blood cultures
• ≥3 with common skin contaminant
3. Evidence of new valve insufficiency
Minor Pyrexia of unknown origin
Subaortic stenosis
Evidence of embolic signs
Evidence of systemic immune-mediated disease
Medium to large breed dog (weight >15 kg)
Positive blood cultures not meeting major criteria
Bartonella spp serology ≥1:1024
TABLE 2 Sample characteristics and basic clinical variables for the study sample consisting of dogs with IE (n = 29), MMVD (n = 27), and
IMD (n = 16)
IE MMVD IMD P value
Number of dogs 29 27 16
Male (%) 15 (52%) 21 (78%) 8 (50%) .08
Age (years) 7.05 (1.86-12.01) 7.84 (3.07-13.59) 4.47 (1.01-12.24) .007
BW (>15 kg) 21 (72.4%) 3 (11/.1%) 9 (56.3%) <.001
Temperature >39.4C (%) 18 (62%) 0 (0%) 8 (50%) <.001
cTnI (ng/mL) 0.69 (0.03-80.8) 0.05 (0.02-0.11) 0.05 (0.03-0.57) <.001
Abbreviations: BW, body weight; cTnI, serum cardiac troponin-I; IE, infective endocarditis; IMD, immune mediated disease; MMVD, myxomatous mitral
valve disease; RT, rectal temperature.
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GraphPad Prism 8 for Mac, GraphPad Software Inc., San Diego, CA);
all tests were 2-tailed and significance was set at P < .05.
3 | RESULTS
The study included 29 dogs with endocarditis, 27 dogs with MMVD,
and 16 dogs with IMD: a total of 72 dogs comprised of 17 different
breeds (Table 2). The IMD group consisted of patients with immune-
mediated hemolytic anemia (IMHA; n = 5), steroid-responsive menin-
gitis arteritis (SRMA; n = 5), immune-mediated thrombocytopenia
(ITP; n = 3), or a combination of IMHA and ITP (n = 3). Within the
MMVD group, 16 patients were stage B1 and 11 were stage B2.7 Fif-
teen MMVD patients had no concurrent disease and the remainder
included those with neurological (n = 4), endocrine (n = 3) orthopedic
(n = 3), dermatological (n = 1), and gastrointestinal (n = 1) disease.
In the IE group, 14/29 dogs (48%) had isolated mitral valve
lesions, 7/29 dogs (24%) had isolated aortic valve lesions, 5/29 dogs
(17%) had both aortic and mitral valve lesions, and 3/29 dogs (10%)
had a mural lesion. Twenty-six of the 29 dogs met the modified Duke
criteria, for a definitive diagnosis of IE. The remaining 3 dogs were
diagnosed with IE by the attending cardiology diplomate. Two of
these dogs had mural lesions which were considered unlikely to be a
thrombus based on changes in appearance over time and evidence of
erosion. The third dog had a mitral lesion in the absence of mitral
regurgitation. There was no significant difference in serum cTnI con-
centrations based on IE lesion location (P = .47). None of the dogs in
the IE group had experienced congestive heart failure.
Blood cultures were obtained in 17/29 dogs diagnosed with IE, of
which 5 dogs (29%) had a positive blood culture with 4 meeting the
major modified Duke criterion and 1 meeting the minor criterion.
The organisms cultured were Actinomyces odontolyticus, Gram-
negative bacilli, Corynebacterium spp, Pasteurella multocida, and Strep-
tococcus spp.
Dogs in the MMVD group were older than those with IMD (7.84
[3.07-13.59] years vs 4.47 [1.01-12.24] years, respectively; P = .01).
Fewer dogs weighing >15 kg were present in the MMVD group (11%)
compared to the IE group (72%, P < .001) and IMD group (56%,
P = .002). No difference in proportion of dogs presenting with pyrexia
was detected between the dogs in IE and IMD groups (62% IE vs 50%
IMD, P = .27).
Significant differences in serum cTnI concentrations were
detected between the 3 groups (P ≤ .001) with cTnI concentrations
being higher in dogs with IE than in those with MMVD (0.69 ng/mL
[0.03-80.8] vs 0.05 ng/mL [0.02-0.11], P < .001) or those with IMD
(0.69 ng/mL [0.03-80.8] vs 0.05 ng/mL [0.03-0.57], P < .001). Addi-
tionally, serum cTnI concentration was also significantly higher in dogs
with IE when compared to dogs with stage B2 MMVD (n = 11) only
(0.69 ng/mL [0.03-80.8] vs 0.05 ng/mL [0.04-0.11], P < .05). Cardiac
troponin-I concentrations were not significantly different between
the 2 control groups (P = .28; Figure 2).
Serum concentration of cTnI exceeded the reference interval
(<0.1 ng/mL) in 23/29 (79%) dogs with IE, a proportion that was
F IGURE 2 Box and Whisker plot showing the serum
concentration of cardiac troponin-I (cTnI; log transformed for
illustration) in dogs with infective endocarditis (IE, n = 29),
myxomatous mitral valve disease (MMVD, n = 27), and immune-
mediate diseases (IMD, n = 16). The concentration of cTnI was not
significantly different between the 2 non-IE groups (P = .28)
TABLE 3 Frequency with which clinical findings were met for
each of the modified Duke criteria in the group of 29 dogs with
endocarditis, in addition to the 2 proposed cutoffs for cardiac
troponin-I concentrations (the upper reference limit of the assays at
>0.1 ng/mL, and the suggested cut-off of >0.625 ng/mL)
Modified Duke criteria Number of dogs with IE
Echocardiographic evidence 29 (100%)
Novel valve insufficiency 22 (76%)
Major blood culture 6 of 17 (35%)
Temperature >39.4C 18 (62%)
Weight >15 kg 21 (72%)
Predisposing factor 7 (24%)
Thromboembolic disease 10 (36%)
Immune-mediated disease 7 (24%)
Minor blood culture 3 of 17 (18%)
Bartonella serology 1 of 5 (20%)
cTnI (>0.1 ng/mL) 23 (79%)
cTnI (>0.625 ng/mL) 15 (52%)
Abbreviations: cTnI, serum cardiac troponin-I; IE, infective endocarditis.
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higher than that observed for any of the individual major or minor
modified Duke criteria other than “typical echocardiographic lesion”
(Table 3). Of the combined control group dogs (n = 43), serum cTnI
concentrations were >0.1 ng/mL in 4 animals: 1 from the MMVD
group and 3 from the IMD group.
Receiver operator characteristic curve analysis demonstrated that
elevated serum cTnI was a moderately accurate predictor of endocardi-
tis in this study sample (area under the curve 0.857 [95% confidence
interval [CI] 0.745-0.968], P < .001; Figure 3). A serum cTnI concentra-
tion of ≥0.125 ng/mL yielded the highest combined sensitivity (79%;
95% CI 60%-91%) and specificity (98%; 95% CI 86%-100%). A serum
cTnI concentration cutoff of 0.625 ng/mL yielded a sensitivity of 52%
(95% CI 33%-70%) and a specificity of 100% (95% CI 90%-100%).
Median follow-up time for dogs in the present study was 47 days
(0-1370 days). At the time of follow-up, 20/29 (69%) of the patients
with endocarditis had died, with euthanasia prompted by clinical signs
the cause of death in all cases. All dogs with MMVD and IMD were
alive at time of follow-up. Median follow-up times for MMVD and
IMD patients were 182 days (0-1143 days) and 47 days (3-139 days),
respectively. Median survival time for dogs in the IE group was
63 days (0-1370 days). Cox proportional hazards analysis revealed no
significant association between survival time and serum cTnI
concentration in patients with endocarditis (hazard ratio 1.013, 95%
CI 0.993-1.034, P = .2).
4 | DISCUSSION
In this sample of dogs, cTnI proved to be a useful tool to help distin-
guish dogs with IE when compared to control groups of dogs with
other echocardiographic valve lesions (MMVD) and dogs with sys-
temic inflammatory disease (IMD). Specifically, a cutoff value of
0.625 ng/mL had 100% specificity in this study sample. There was no
association between serum cTnI concentrations and survival time in
dogs with IE.
Since the diagnosis of IE is predominantly based on a scoring
system—the modified Duke criteria4—any additional tests which may
assist in adding weight to a diagnosis of IE are valuable, especially for
vets with limited experience of this disease. In this study, we selected
2 control groups in an attempt to mimic clinical scenarios in which IE
might be considered a differential diagnosis. For example, heart mur-
murs are commonly reported in dogs with IE,1,22,23 IMHA,24 and ITP25
and are an essential component of stage-B MMVD.7 Other commonly
shared clinical features of IE and IMD include pyrexia2,24,26 and
embolic disease,2,22,27,28 which were both observed in IE patients in
this study (Table 3).
In a clinical scenario, echocardiography is indicated in a dog pre-
senting with pyrexia of unknown origin, thromboembolic signs, and
evidence of IMD to further investigate the possibility of IE; in this
case, all 3 signs are minor components of the modified Duke criteria,
but are also common in dogs with noncardiac disease. Since echocar-
diographic differentiation of vegetative and myxomatous lesions is
dependent on operator experience and the quality of the ultrasound
image obtained (training and machine factors), we propose that the
addition of serum cTnI measurement—a widely available and objective
assay—could provide valuable further support for a diagnosis of IE,
especially if >0.625 ng/mL.
The results of the ROC curve analysis demonstrated that serum
cTnI concentrations differentiated dogs with IE from the control
groups with moderate accuracy. Furthermore, a high proportion of
dogs with IE exhibited increased serum cTnI concentration (23/29,
79%) and 100% specificity was observed when using a cutoff of
>0.625 ng/mL. Therefore, we propose that serum cTnI concentration
>0.625 ng/mL could be considered as a minor Duke criterion in dogs.
However, the low sensitivity (52%) of this cutoff indicates that a
serum cTnI concentration below 0.625 ng/mL does not exclude IE
from the list of differentials.
A number of disorders can cause increased serum concentrations
of cTnI, including primary cardiac disease,8,10,11,29 azotemia and sys-
temic disease,12 pyometra,14 and gastric dilatation and volvulus.13 In
this study, no dog with IE had to be excluded because of azotemia
(defined as creatinine >1.40 mg/dL) and none had evidence of sys-
temic disease that was not secondary to IE. Indeed, no alternative
cause for increases in cTnI could be identified in any dog with IE. The
F IGURE 3 Receiver operator characteristic curve, demonstrating
diagnostic performance of serum cardiac troponin-I in dogs with
endocarditis. This was a moderately accurate predictor of endocarditis
in this sample (area under the curve 0.857 [95% confidence interval
(CI) 0.745-0.968], P < .001)
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pathophysiologic basis of increases in cTnI in dogs with IE remains
unclear. As cTnI is an intracellular myocardial protein,9 its increases
might be because of a localized myocarditis caused by inflammatory
mediators, septic or thrombotic coronary emboli, or myocardial
involvement of the infection itself; all of which have been proposed as
possible mechanisms in humans.18,19
Dogs with MMVD can have increased cTnI concentrations,10,30
depending on disease stage and severity. Immune-mediated dis-
eases such as SRMA31 and IMHA32 can also cause an increase in
cTnI concentrations which often normalize after the treatment of
the primary condition. In our study, although 1/27 dogs with
MMVD and 3/16 dogs with IMD had elevated serum cTnI concen-
trations, significant differences remained detectable between these
groups and dogs with IE. Furthermore, the difference in serum cTnI
concentration between IE and MMVD groups remained significant
when only stage B2 dogs were included, indicating that cTnI is
useful in differentiating dogs with IE from more advanced preclini-
cal valvular disease. Concentrations overlapped between all groups
and to maximize the predictive value of serum cTnI measurement
in the diagnosis of IE, we recommend a cutoff value >0.625 ng/mL
as a practically useful tool, as this did not yield any false-positive
results in this study sample.
The diagnostic utility of serum cTnI measurement in our study
reflects the results of studies on IE in humans. However, unlike these
studies,16,17,19 we did not find any association between serum cTnI con-
centration and outcome. This difference might be because of species dif-
ferences in host immune response, differences in available treatments,
different causative infectious agents associated with IE, or different
disease-lifestyle associations; for example, IE in humans is commonly
associated with IV use of recreational drugs.33,34 However, as the cause
of death in all our IE dogs was euthanasia, we must also consider the
influence of financial and emotional factors in determining outcome.
Limitations of this study were typical for its retrospective design.
Results were obtained from dogs diagnosed in referral centers in
1 country, and therefore sample demographics and the results of sur-
vival analysis may not be generalizable to general practice or different
geographic regions. However, our sample of dogs represented an
authentic selection of naturally occurring cases of IE with no apparent
selection bias other than the final diagnosis being made in the referral
setting. The IMD group was small and heterogeneous, with only
16 dogs and 3 different diagnoses. Group sizes are relatively small,
but the number of dogs with IE is reasonable in the context of the
published literature.
To maximize the number of cases within the IE group, dogs were
enrolled from 2 centers. Because these centers were located within
200 miles of one another, the differences in the background popula-
tion were likely to be minimal and therefore comparison with a control
group from only 1 center should not affect our analysis. Recruiting IE
cases from 2 institutions also meant that 2 different assays for cTnI
were used for measurements in the IE group. Although the sample
handling and analysis technique were similar, the numbers might not
be directly comparable and so our cutoff values established should be
considered as estimates rather than a definitive number. As with any
test result, veterinarians must contextualize the measurement within
the overall clinical picture of the animal under their care. In addition,
increased bilirubin concentration can interfere with the measurement
of cTnI when using 1 of these 2 assays. In this study, none of the IE
dogs were hyperbilirubinemic and, although dogs with IMHA often
have an increased concentration of bilirubin, cTnI from all dogs with
IMD was measured using the other assay, which does not suffer from
the same interference.
Cardiac troponin-I has a half-life of just under 2 hours in the
dog35 In the current study, we chose a time period of 7-days before
or after diagnosis in which a sample could be obtained for inclusion in
the study. We chose this relatively wide window because IE is not an
acute insult, but likely to be associated with more chronic inflamma-
tion, over several days or weeks, rather than an acute event, unlike a
myocardial infarction in humans, where cTnI would wane within hours
of a single insult. Additionally, the clinical signs of IE can be
nonspecific,1 and it is common for dogs to remain undiagnosed for
days or weeks before investigation by an experienced clinician. There-
fore, we propose that our 2-week window was reasonable and reflec-
tive of using the test in general practice.
We chose not to include dogs with stage-C MMVD in our
study. This was because we wanted to investigate whether the
measurement of serum cTnI concentration would prove useful in
differentiating dogs with IE and dogs with earlier MMVD that had
more subtle valve lesions than tend to be present in stage C. Also,
overt signs of heart failure might allow more straightforward locali-
zation of disease to the heart. This means that we have not
accounted for how congestive heart failure might increase serum
cTnI concentration in dogs with MMVD and those with IE causing
severe enough valve dysfunction to cause congestive signs. How-
ever, since none of the dogs within the IE group had presented
with signs of congestive heart failure, stage-B MMVD served as an
appropriate comparison.
Despite these limitations, these data suggest that measure-
ment of serum cTnI concentration might be helpful in the diagno-
sis of IE. Further studies in a wider sample of dogs would be
helpful to validate our findings, especially if carried out prospec-
tively using a single assay and standardized sample-handling tech-
nique. It would also be worth investigating if serum cTnI
concentration improved diagnostic confidence for IE. This could
be performed using a case-scenario questionnaire to evaluate the
decision-making of veterinarians.
In conclusion, the results of this study demonstrate that
serum cTnI concentrations are significantly higher in dogs with
IE compared to control samples of dogs with preclinical MMVD
or IMD. Care should be taken not to infer a diagnosis of IE
based solely on cTnI concentration. However, based on these
results, we propose that in dogs with a compatible clinical pre-
sentation, serum cTnI concentrations >0.625 ng/mL are support-
ive of a diagnosis of IE.
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